For the year ending 2025-12-31, LCTX has $112,584K in assets. $69,238K in debts. $40,791K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 40,791 | |||
| Marketable securities | 14,990 | |||
| Accounts receivable | 891 | |||
| Prepaid expenses and other current assets | 2,485 | |||
| Total current assets | 59,157 | |||
| Property and equipment, net | 2,566 | |||
| Operating lease right-of-use assets | 2,131 | |||
| Deposits and other long-term assets | 558 | |||
| Goodwill | 10,672 | |||
| Intangible assets, net | 31,700 | |||
| Deferred tax asset, net | 5,800 | |||
| Total assets | 112,584 | |||
| Accounts payable and accrued liabilities | 7,181 | |||
| Operating lease liabilities, current portion | 816 | |||
| Finance lease liabilities, current portion | 37 | |||
| Deferred revenues, current portion | 3,333 | |||
| Total current liabilities | 11,367 | |||
| Deferred tax liability, net | 22 | |||
| Deferred revenues, net of current portion | 12,377 | |||
| Operating lease liabilities, net of current portion | 1,534 | |||
| Finance lease liabilities, net of current portion | 32 | |||
| Warrant liabilities | 43,906 | |||
| Total liabilities | 69,238 | |||
| Common shares, no par value, 450,000 shares authorized as of december 31, 2025 and 2024 243,122 and 220,416 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 515,467 | |||
| Accumulated other comprehensive loss | -3,920 | |||
| Accumulated deficit | -466,998 | |||
| Lineage's shareholders' equity | 44,549 | |||
| Noncontrolling deficit | -1,203 | |||
| Total shareholders equity | 43,346 | |||
| Total liabilities and shareholders equity | 112,584 | |||
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)